Chaperon Selected for Clinical Support Project by National New Drug Development Foundation for COVID-19 Treatment

원본보기 아이콘

[Asia Economy Reporter Lee Gwan-joo] Immunotherapy drug development bio company Shaperon announced on the 18th that its COVID-19 treatment 'Nusepin' has been selected as a clinical support project for COVID-19 treatments by the Korea Drug Development Fund (KDDF) and that an agreement has been signed.

Shaperon previously received approval from the Ministry of Food and Drug Safety for multinational Phase 2b and 3 clinical trials of Nusepin and is preparing to start domestic clinical trials.

With this project selection, Shaperon will receive 9.1 billion KRW in research funding over one year. The ultimate goal is to complete the Phase 2b clinical trial verifying the dosage, efficacy, and safety of Nusepin in hospitalized patients with moderate or higher severity COVID-19 pneumonia.

Shaperon submitted its preliminary review application for KOSDAQ listing last January and is currently undergoing the initial public offering (IPO) process aiming for listing this year.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.